Joaquim Bellmunt

Joaquim Bellmunt is an internationally recognized urothelial cancer specialist who chaired the KEYNOTE-045 trial demonstrating survival benefit of pembrolizumab over chemotherapy in previously treated advanced urothelial cancer, leading to FDA approval. He has contributed extensively to clinical trials in bladder and upper urinary tract cancers spanning multiple therapeutic modalities. He co-authored major European and international treatment guidelines for urothelial malignancies. He has been a leading investigator in FGFR-targeted therapy trials for FGFR-altered urothelial cancer.